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Abstract  
The antibiotic pipeline is running dry and infectious disease remains a major threat to 
public health. An efficient strategy to stay ahead of rapidly adapting pathogens 
should include approaches that replace, complement, or enhance the effect of both 
current and novel antimicrobial compounds. In recent years, a number of innovative 
approaches managing disease without the aid of traditional antibiotics and without 
eliminating the pathogens directly have emerged. These include disabling pathogen 
virulence-factors, increasing host tissue damage control, or altering the microbiota to 
provide colonisation resistance, immune resistance or disease tolerance against 
pathogens. We discuss the therapeutic potential of these approaches and examine 
their possible consequences for pathogen evolution. To guarantee a longer half-life 
of these alternatives to directly killing pathogens, and to gain a full understanding of 
their population-level consequences, we encourage future work to incorporate 
evolutionary perspectives into the development of these treatments.  
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1. Beyond killing 
The emergence of widespread resistance to antibiotics is driving an intense search 
for alternative therapeutic approaches against bacterial pathogens [1,2]. A major part 
of this effort focuses on discovering novel antimicrobial drugs[3,4]. However, the 
evolution of drug resistance appears to be inevitable (despite some interesting 
exceptions such as the continued susceptibility of Treponema pallidum [5] and 
Streptococcus pyogenes [6] to penicillin), meaning that novel antimicrobial drugs will 
only offer at best a temporary solution[7,8]. The discovery of novel antimicrobial 
drugs, while crucial, should advance alongside approaches that minimize the 
evolutionary potential of pathogens[9–11]. The high killing potential of current drugs 
is one of the strongest sources of selection exerted on pathogens, as evidenced by 
the rapid and consistent evolution of antibiotic resistance [8]. The reason why 
antimicrobial drugs lead to the evolution of drug resistance is simply natural 
selection, which leaves behind the pathogen strains most capable of surviving the 
deleterious effects of antimicrobial compounds. Novel therapeutic approaches should 
therefore aim to minimize the impact of this evolutionary response, and one way to 
do so is to control infections without killing pathogens directly. Here, we review three 
promising advances that move beyond direct killing to reduce disease severity, 
including: (i) the targeting of the effectors of pathogenicity rather than the pathogen 
itself; (ii) improving tissue damage control, thereby improving the host’s capacity to 
tolerate pathogens; and (iii) targeting the microbiome in order to build a natural line of 
defence against pathogens. For each approach, we introduce its mode of action, 
present key examples, and discuss putative selection pressures and evolutionary 
responses to treatment. Finally, we discuss the applicability of these approaches, 
and emphasize that it is imperative to investigate in more detail the longer-term 
evolutionary consequences of such treatments. 
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2. Disarming pathogen virulence factors 
One promising alternative to classic antibiotics is to focus on strategies reducing 
pathogen virulence, which we define in the broadest sense as the degree of 
pathology and overall disease symptoms experienced during infection.  Pathogen 
virulence can be targeted at least at three levels (Figure 1)[12–14], by interfering 
with: (a) pathogen adhesion, which is important for host invasion and colonization; (b) 
quorum sensing, a cell-to-cell signalling system used by bacteria to coordinate the 
secretion of virulence factors; and (c) expression and activity of virulence factors, 
which are usually secreted proteins or secondary metabolites that act directly or 
indirectly to cause tissue dysfunction and/or damage[9,12]. Approaches belonging to 
these categories are called anti-virulence therapies, as they deprive essential 
virulence factors from infections without directly killing the pathogens themselves.  
  
One example of such an anti-virulence drug approach was recently described in 
Clostridium difficile infections, where a synthetic compound called ebselen was found 
to be effective in inhibiting two major virulence-causing toxins (TcdA and TcdB)[15]. 
When tested in a mouse model, it was shown that ebselen reduced the disease 
severity of Clostridium difficile infections without affecting the pathogen load[15]. 
Another example of pharmacological approaches targeting virulence factors is the 
use of phosphonosulphonates to treat Staphyloccocus aureus infection. These 
compounds inhibit the production of staphyloxanthin, a bacterial anti-oxidant pigment 
that normally protects S. aureus from reactive oxygen species and neutrophil-based 
killing. When staphyloxanthin is inhibited, S. aureus becomes vulnerable to innate 
immune resistance mechanisms, without interfering with commensal conspecifics 
[16]. Finally, a recent study successfully targeted the iron-scavenging capacity of 
Pseudomonas aeruginosa, through the administration of gallium, an iron-mimic, 
which binds to iron-scavenging siderophores produced by the pathogen. Gallium 
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disables siderophores outside the cells, thereby preventing iron uptake and inducing 
iron-starvation [17]. While these examples represent novel approaches to manage 
infection, it is also worth noting that some antibiotics, in addition to killing, can also 
exhibit anti-virulence effects. For example, both clindamycin and gentamycin can 
reduce the toxin production underlying toxic shock syndrome [18], and azithromycin 
can reduce expression of virulence genes in P. aeruginosa  [19]. 
 
The above examples illustrate that effective anti-virulence treatments already exist. 
However, they also show that the initial idea of disarming pathogens without curbing 
their fitness might often not hold. For instance, phosphonosulphonates expose 
bacteria to host-mediated removal, and gallium induces iron starvation. Hence, the 
question about the evolutionary robustness of these therapies, which is required for 
their sustainable use in the long-term, needs closer examination. Theoretical work 
suggests that the evolution of resistance against anti-virulence is restricted if 
disarming a virulence factor has no fitness consequences for the pathogen[12]. Here, 
resistant variants might evolve but should not spread because they enjoy no fitness 
advantage compared to the susceptible wild type. While it is difficult to imagine that 
bacteria express traits that have absolutely no effect on their growth and/or survival, 
there are at least a few examples (see the above-mentioned ebselen therapy, but 
also [20]) that seem to meet this criterion. Alternatively, it has been suggested that 
drug resistance against anti-virulence treatments should not easily spread if the 
therapy targets a virulence factor that is secreted and shared between pathogen 
individuals [21,22]. In this scenario resistant mutants might restore production of the 
drug-inhibited virulence factor or produce a modified, more potent, version of it 
[17,23]. However, these mutants should not spread because the freshly produced 
virulence factors are shared among cells and thereby benefit mutant and susceptible 
wild-type individuals alike. The above-mentioned gallium therapy falls within that 
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category, because it targets secreted and publically shared siderophores. 
Evolutionary experiments indeed revealed no detectable signs of resistance against 
gallium, indicating that even drugs reducing pathogen growth can be evolutionarily 
robust, if they target shared virulence factors [17]. In addition to reducing the 
potential for resistance to spread, one could also seek to reduce the probability that 
resistant mutants arise in the first place. While this point is typically considered in 
antimicrobial drug design[11], it has particular relevance for anti-virulence drugs that 
target secreted virulence factors outside the cell. The idea is simple: extra-cellular 
modes of drug actions should prevent common resistance mechanisms, such as 
limitation of drug entry, increased drug efflux or intra-cellular drug degradation, from 
operating [24]. Extra-cellular quenching of siderophores or quorum-sensing signals 
are approaches belonging to this category of treatments [17,25].  
 
These considerations suggest that anti-virulence therapies can be evolutionarily 
more robust than classic antibiotic treatments if the virulence factor in question: (a) 
has marginal fitness effects; (b) is shared among individuals; (c) and/or is disabled 
outside the cell. If this concept holds true we could not only use it as a guideline for 
future drug design, but also identify the approaches that are less likely to be 
evolutionarily robust. For instance, the above-described phosphonosulphonates 
therapy to treat S. aureus infection [6] does not belong to any of the three categories, 
as this therapy reduces pathogen fitness and targets a private and not a secreted 
shared virulence factor. Thus, it seems conceivable that resistance in the form of 
restoration of the defence against the host’s innate immune system could quite easily 
evolve. However, strong conclusions on the evolutionary robustness of anti-virulence 
therapies are currently not possible because we simply lack estimates of the strength 
selection imposed by different anti-virulence treatments on pathogens. This calls for 
studies that actually measure the selection pressures exerted by the different 
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treatment schemes also taking into account any possible pleiotropic effects including 
undesirable changes in pathogen or host behaviour.  
 
3. Targeting tissue damage control mechanisms to enhance host tolerance of 
infections  
In this section, we examine therapeutic approaches that strengthen the host’s ability 
to control and repair tissue damage. While host mechanisms of pathogen elimination 
such as immune-mediated clearance are key to defence against pathogens, 
additional defence mechanisms which prevent, repair and limit the extent of tissue 
damage are also required to control infections[26]. Tissue damage control 
mechanisms are interesting from a therapeutic perspective because they enhance 
the capacity of an infected host to minimize disease severity, that is to tolerate the 
pathogenic effects of infection[27,28]. Disease tolerance may be defined as the 
host’s ability to maintain health when faced with increasing pathogen loads[27–29], 
and tissue damage control is one way to maintain health during infection[26]. 
Prevention or repair of tissue damage has been shown to confer disease tolerance of 
severe sepsis caused by polymicrobial infections[30], malaria caused by Plasmodium 
infection[31] and for co-infections by influenza virus and bacteria leading to 
pneumonia[32]. 
 
Recently, specific pharmacologic agents have been developed to specifically target 
tissue damage control mechanisms and to confer tolerance of infectious diseases. 
For example, a low dose regimen of anthracyclines has been shown to provide a 
protective effect during sepsis, preventing multi-organ dysfunction and damage even 
though the treatment does not reduce the bacterial load[33]. This example of tissue 
damage control leading to increased disease tolerance arises because 
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anthracyclines induce a DNA-damage response that leads to the activation of 
autophagy-related pathways and reduction of systemic inflammation, the main cause 
of multi-organ dysfunction and damage associated with the pathogenesis of sepsis 
[33]. Targeting tissue damage control mechanisms therapeutically, as demonstrated 
as a proof of principle for anthracyclines could therefore be a promising alternative or 
addition to the widespread use of antibiotics if it can minimize the severity of infection 
while helping the host immune response to clear the infection. In many ways, treating 
the symptoms of infection rather than focusing on killing the root cause is not a new 
concept. Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used for the 
alleviation of symptoms for various infectious diseases. By treating the symptoms of 
infection without eliminating pathogens, these treatments are essentially tolerance-
boosting therapies [9]. 
  
One approach to uncover novel therapeutic targets for tissue damage control is to 
unravel the underlying causes for the enormous variation in disease tolerance that is 
often observed between species or even sub-species in their response to zoonotic 
pathogens. For example, bats, mice and humans are susceptible to infection by the 
Ebola virus, but these species have very different disease outcomes. It has been 
speculated that bats are especially capable of tolerating many zoonotic viruses 
through a combination of attenuated immunity - which reduces potential 
immunopathology - and the ability to minimize oxidative stress - an adaptation to 
metabolically costly activities like flight [34,35]. The combined result is incomplete 
viral clearance and reduced immunopathology, which has been suggested as a 
plausible explanation for bats being such accomplished viral reservoirs, although 
concrete data to this effect is currently lacking. One way to compare groups of hosts 
that may differ in their ability to limit damage during infection is to obtain health read 
outs (e.g. survival, anaemia, immune markers) for increasing pathogen doses under 
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controlled experimental conditions. These groups of hosts (e.g. different species as 
in the Ebola example, or human patients receiving damage limitation therapies) may 
differ in various parameters of this pathogen dose-host health response, including 
host vigour (the baseline level of health in the absence of infection), sensitivity to 
increases in pathogen load (the infection dose at which host suffer a severe decline 
in health) the rate at which host health decreases with increasing pathogen loads 
(the slope of the decline in health), or the severity of infection, which determines how 
sick a host can get during infection (Figure 2). Variation in each of these parameters 
may reflect distinct underlying mechanisms that either promote greater prevention of 
damage during infection, or increase damage repair after the damage has been done 
[28]. If we were able to identify novel mechanisms of disease tolerance, we could 
then seek to develop therapies that enhance them with drugs that are likely to be 
more evolution-proof than conventional antibiotics. 
 
Finally, it has been recognised that pathogen elimination mechanisms can work 
together with host mechanisms that promote tissue damage control and increase 
disease tolerance[29,36,37]. The idea is thus to develop therapeutics that strengthen 
the interaction between elimination and repair, especially in cases where pathogen 
elimination mechanisms fail, on their own, to reduce the pathogenesis of infectious 
diseases. For example, recent studies on mice infected with Listeria monocytogenes 
revealed that both the early immune-driven process leading to pathogen elimination 
and mechanisms that maintain host health at later stages of infection are important 
hallmarks for survival[38].  These insights were gained by tracing individual health 
trajectories during infection, constructed by plotting time-ordered, individual repeated 
measures of pathogen load against health throughout infection[39,40]. This novel 
analytical approach can be used to monitor the interplay between pathogen 
elimination and host repair mechanisms and their combined effect on infection 
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outcome, thus illustrating an individual’s infection path towards either recovery or 
death. The Listeria study described above[38] demonstrated that survivors and non-
survivors of infection can assume divergent infection paths several days prior to 
death and that these paths are at least partly genetically determined[38].  This would 
suggest that one could predict the likely infection outcome based on characteristics 
of the infection paths at earlier stages of infection. Future studies should aim at 
determining the range of physiologically possible health trajectories associated with 
different types and outcomes of infections and at identifying the key regulatory 
mechanisms that are responsible for divergence in infection paths.  
 
Alternatively to sequential dependence illustrated in [38], mechanisms that eliminate 
pathogens may overlap with tissue damage control mechanisms as illustrated by the 
immune response to parasitic worms. These parasites typically do not replicate in the 
host and, instead, represent a very different kind of threat; they typically injure or 
damage host tissues in order to enter, migrate or feed. Thus, infection by these 
parasites requires that any tissue damage be rapidly repaired and parasite numbers 
stay below a threshold that would compromise host fitness [41,42]. This dual 
requirement has led to an immune response that relies on overlapping pathways to 
kill or expel the parasites, and to repair the damage they cause [43]. Thus the anti-
worm effector responses have likely evolved directly out of wound healing pathways 
that confer tissue damage control [41,42].   
 
While beneficial for the infected individual, the population-level consequences for 
pathogen evolution and spread of boosting host tolerance by improving tissue 
damage control have received relatively little attention[9]. The link between damage 
control, disease spread and pathogen evolution becomes intuitive when one 
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recognises that the ability of a pathogen to replicate and infect other individuals is 
constrained by how much damage it causes before its host dies (virulence) and how 
this level of virulence affect host evolutionary fitness[44]. Limiting tissue damage 
makes hosts healthier, but without eliminating pathogens directly potentially turns 
these hosts into disease reservoirs or silent spreaders[35,45]. Evolutionary and 
epidemiological theory suggests that for infections where there is a strong link 
between virulence (infection-induced mortality) and pathogen fitness (the ability to 
replicate and spread to other hosts), therapies that limit tissue damage during 
infection can lead to the evolution of more virulent and also more prevalent 
infections[9,46]. This link between virulence and pathogen fitness is particularly 
expected for obligate pathogens, where transmission between hosts is the main 
determinant of pathogen fitness Conversely, this link is supposedly weaker for 
facultative pathogens, which can grow in non-disease contexts [47] and tolerance-
boosting therapies are therefore expected to have fewer negative evolutionary 
consequences in this group of pathogens. While these considerations suggest some 
caution, and highlight that it is necessary to balance the immediate benefits of 
alleviating virulence for individual patients with the potential longer-term costs for the 
population as a whole, the ubiquitous problem of antibiotic resistance makes it worth 
investigating if there are specific clinical scenarios where therapies promoting tissue 
damage control may be beneficial at both the individual and population levels.  
 
4. Manipulating commensal microbiota to reduce infection 
A host’s health can be greatly impacted by its microbiome [48]. This realisation has 
spurred momentum into studying the effects of microbes on animal and human 
biology, notably their role in altering host susceptibility to infection by different 
pathogens [49–52]. Bacteria, whether pathogenic or commensal, have evolved a 
 by guest on M
arch 28, 2016
http://em
ph.oxfordjournals.org/
D
ow
nloaded from
 
  
battery of mechanisms to remove competitors and colonise their host, including the 
release of toxins and phage that directly kill competitors or provocation of host 
immune responses to which they are resistant, but their competitors are susceptible. 
Amongst pathogens prominent examples include the release of shiga toxin encoding 
phage in shigatoxinagenic Escherichia coli[53], production of the toxin pyocyanin by 
Pseudomonas aeruginosa[54], recruitment of neutrophils into the paranasal spaces 
by Haemophilus influenza[55], and suicidal invasion of the gut tissue to provoke 
inflammation by Salmonella enterica serovar Typhimurium[56]. These examples 
show that there are strong competitive interactions between the commensal 
microbiome and pathogens, which opens the possibility for therapeutic interventions 
aiming at strengthening the microbiome and weakening the invasion potential of 
pathogens[57]. 
 
One prominent example of how protective bacteria can be used in therapeutic 
interventions is the treatment of Clostridium difficile infections in humans. Briefly, C. 
difficile colitis occurs following perturbation of the host’s commensal microbiota, most 
commonly due to antibiotic treatment of unrelated infections[58]. A combination of 
evolved antibiotic resistance and intrinsic resistance factors such as spore formation, 
make that traditional antibiotic treatment often fails to eradicate C. difficile colitis[59]. 
An alternative therapy of ‘faecal transplant’ or bacteriotherapy, whereby the 
microbiome of the patient is repopulated using faecal material from healthy donors, 
has recently shown great promise, with high success rates in curing otherwise 
recurrent infections[60,61]. Furthermore, the ecological basis of the success of this 
treatment has been mechanistically disentangled using a combination of sampling of 
human patients and experiments with a mouse model[62]. This study has shown that 
it is C. difficle’s cogener C. scindens that protects against C. difficile infection by 
biosynthesis of secondary bile acids, which suppress C. difficile growth[62]. This 
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work offers hope of using precise alterations to the human microbiota in order to 
protect against C. difficile infection. 
 
Bacteriotherapy is not only a feasible defence against C. difficile infection; similar 
modifications of the gut microbiome have been suggested to treat a range of other 
infections. Enterococcus faecalis is a leading cause of hospital-acquired and often 
systemic infections with an increasing frequency of multi-drug resistant strains. 
However, many E. faecalis strains can also be a constituent of the normal healthy gut 
flora. Recent work in a mouse model of E. faecalis infection has shown that 
engineering strains of E. faecalis that express bacteriocin 21 encoded on 
conjugation-defective plasmids can clear infections of vancomycin resistant E. 
faecalis strains[63]. Strikingly, this treatment had no detectable effect on the 
composition of other species in the microbiota, with the treatment simply resulting in 
replacement of the virulent multi-drug resistant strain with a drug-susceptible 
commensal[63]. Similarly, it has been suggested that introducing commensal strains 
of Staphylococcus epidermidis could help reduce nasal carriage of drug resistant S. 
aureus via competitive exclusion[64]. As an alternative to genetic engineering, a 
novel approach would be to explore the degree to which natural variation in 
protective traits of single microbe species[57,65] or whole microbiomes can be 
engineered through artificial selection. Experimental evolution approaches might 
prove very powerful in generating protective microbes and microbiomes with specific 
effects on disease defence. 
 
These approaches are highly complementary to anti-virulence and tolerance 
increasing treatments, as introducing natural or engineered bacteria to a patient may 
be used to block pathogen virulence or promote tolerance. For instance, Vibrio 
cholerae’s virulence is negatively regulated by one of its quorum sensing molecules, 
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cholera autoinducer 1 (CA-1). Introducing an engineered commensal Escherichia coli 
strain that also produces CA-1 has been show to greatly reduce V. cholera virulence 
in a mouse model, limiting binding of cholera toxin to the intestine by 80% and 
reducing V. cholera abundance by 69%, ultimately leading to an increase in host 
survival of 92%[66]. Specific components of the gut microbiota have also been 
shown to modulate disease tolerance[67]. For example, gut colonization by 
Escherichia coli (E. coli) strain O21:H+ confers a survival advantage against enteric 
and lung bacterial infections in mice without interfering with pathogen load, thus 
revealing that this E. coli strain induces host mechanisms that result in disease 
tolerance of bacterial infections[67]. The exact mechanism via which this occurs 
involves sensing of E. coli O21:H+ triggering the induction of insulin-like Growth 
Factor-1 (IGF-1), which acts systemically to alleviate muscle wasting[67]. It is this 
tissue damage control mechanism – in this case stimulated by a modification of the 
gut microbiota - that accounts for the survival advantage conferred by E. coli O21:H+ 
against bacterial infections. 
 
These examples highlight a great promise in effective microbiome-control therapies, 
yet understanding their evolutionary consequences is vital for assessing their 
suitability and sustainability as therapeutic approaches against infectious diseases. 
So far the consequences of alteration of the microbiome for pathogen evolution and 
epidemiology have received little attention[68], and we can therefore only speculate 
about possible evolutionary responses to microbiome therapy. Since these 
treatments aim to strengthen the opponents of the pathogen, they may create 
selection for increased expression of the pathogen’s arsenal of weapons used to 
clear commensals, potentially increasing their virulence. This adaptation of ‘fighting 
back’ is a likely outcome of pathogen evolution in cases where toxins are the direct 
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causes of virulence in humans and are required to clear commensal competitors[68]. 
In addition to evolving to fight back against the strengthened microbiome, pathogens 
could evolve greater protection against its competitive effects. A recent experimental 
evolution study co-culturing S. aureus with the competitor S. epidermidis has shown 
that S. aureus can evolve resistance to the toxins used by S. epidermidis for 
competitive exclusion[64]. This study not only directly demonstrates that pathogens 
can evolve in response to the introduction of competitors, but highlights the utility of 
experimental evolution approaches to predict to potential responses to novel 
treatments. Additionally, one of the most common responses of bacteria to resist 
ecological competition is to form biofilms, which also greatly increase their resistance 
to antibiotics[69], and increases in biofilm formation could conceivably evolve in 
response to microbiome therapy. These considerations emphasize that, although 
bacteriotherapy is increasingly explored as a promising therapeutic approach against 
infections that are recalcitrant to traditional antibiotics, it is critical that their 
evolutionary consequences are elucidated to prevent unwanted repercussions arising 
from pathogen evolution.  
 
Conclusions 
Pathogen evolution and the resulting resistance against treatments present a serious 
challenge to public health. Here, we propose three therapeutic approaches 
(disarming pathogens, boosting the host’s damage repair systems, and strengthening 
the natural microbiome) that move away from direct pathogen killing to strategies that 
manage rather than eradicate infections. These approaches represent a fundamental 
conceptual shift in the way we think about infections, and could potentially be applied 
to both acute and chronic infections. While all approaches look promising, a number 
of important questions remain to be addressed (Box 1). Because drug resistance 
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evolution involves fundamental biological processes such as genetic variation and 
natural selection, managing these issues will only be successful if they are 
systematically addressed within an evolutionary ecology framework. First, a detailed 
mechanistic understanding of how virulence is mediated, and how hosts mount repair 
responses and interact with their microbiome is required. Only this knowledge will 
allow us to identify the most appropriate targets for evolutionarily robust and efficient 
therapies. In addition, interactions between the three approaches should be better 
understood. After all, virulence factors cause tissue damage and interfere with the 
microbiome, which opens the possibility for integrative therapies that simultaneously 
weaken the pathogen and strengthen the host. Second, a systematic theoretical 
framework is needed which examines the evolutionary robustness of the different 
approaches. It is important to realize that whatever therapy is used, it is likely to 
modify the within-host environment, and therefore inevitably imposes a different 
selection pressure on pathogens. Microbial adaptation to environmental changes, 
such as those imposed by therapy simply seems unavoidable, so it is vital that we 
investigate the potential epidemiological and longer-term evolutionary consequences 
of these new approaches to managing infections. Clearly, the urgent need for new 
strategies to fight infectious disease requires a close collaboration between scientists 
from molecular biology, evolutionary biology and medicine.  
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Figure Legends 
Figure 1. Examples of anti-virulence approaches. (A) In a classical infection, bacteria 
adhere to host tissue using their flagella and pilli. They then secrete quorum-sensing 
molecules (red dots) to communicate with nearby cells in order to coordinate the 
secretion of harmful virulence factors (green pentagons), such as toxins and tissue-
degrading enzymes. (B) A potent anti-virulence approach is to prevent bacterial 
adhesion by the administration of hydrophilic compounds (purple layer) [70]. (C) 
Interference with bacterial communication, called quorum-quenching has been 
proposed as another efficient way to control bacterial infections. Numerous drugs 
(yellow half-circles) have been shown to either quench the bacterial signals outside 
the cell or to directly stall signal production within cells [25], (D) Approaches have 
also been developed to target the damaging virulence factors (e.g. siderophores, 
toxins) directly by either suppressing their synthesis or by inhibiting their actions once 
secreted [12]. 
 
Figure 2. When comparing the ability of two different groups of hosts to limit damage 
during infection (for example, a group with or without a damage control therapy), a 
common approach is to analyse how host health changes with increasing infection 
loads for each of the groups of interest. As pathogen loads increase during infection, 
hosts will lose health, going from a state of no symptoms to illness, and in extreme 
cases even death. In its simplest form, this relationship may be linear [29,36], and 
host groups showing steep negative slopes for this reaction norm suffer a loss in 
health with increasing loads, while hosts with flat reaction norms are able to maintain 
health even as pathogen loads increase, and are therefore relatively tolerant. A 
potentially more realistic outcome is a non-linear relationship between host health 
and pathogen load.  Hosts with more efficient damage prevention or repair 
mechanisms are able to maintain a higher level of health during infection (blue line) 
by affecting the sensitivity, slope, or severity of the dose-response curve.  The aim of 
therapies that promote tissue damage control is to flatten these relationships (by 
increasing the period before health plunges and/or lowering the slope). 
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Box 1: Five outstanding questions 
1. What are the types and strengths of selection pressures that anti-virulence, 
tolerance, and microbiome manipulation therapies impose on pathogens? 
2. Which virulence traits should be targeted to minimize selection on 
pathogens? 
3. What are the important components of host disease tolerance, and how can 
they be therapeutically enhanced to suppress disease in concert with host 
pathogen elimination mechanisms? 
4. How can the human microbiome be manipulated/strengthened to efficiently 
compete with pathogens? 
5. How do the three therapeutic approaches interact, and are there ways to 
synergistically combine them? 
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Anti-adhesion Standard infection A B Quorum quenching C Virulence factor inhibition D
Figure X. Examples of anti-virulence approaches. (A) In a classical infection, bacteria adhere to host tissue 
using their flagella and pilli. They then secrete quorum-sensing molecules (red dots) to communicate with nearby 
cells in order to coordinate the secretion of harmful virulence factors (green pentagons), such as toxins and 
tissue-degrading enzymes. (B) A potent anti-virulence approach is to prevent bacterial adhesion by the 
administration of hydrophilic compounds (purple layer) (e.g. Valle et al. 2006 PNAS). (C) Interference with 
bacterial communication has been proposed as another efficient way to control bacterial infections. Numerous 
drugs (yellow half-circles) have been shown to either quench the bacterial signals outside the cell or to directly 
stall signal production within cells (LaSarre & Federle 2013 MMBR). (D) Approaches have also been developed 
to target the damaging virulence factors (e.g. siderophores, toxins) directly by either suppressing their synthesis 
or by inhibiting their actions once secreted. 
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